Prevention of taste alterations in patients with cancer receiving Paclitaxel- or Oxaliplatin-based chemotherapy — A pilot trial of cannabidiol
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Prevention of taste alterations in patients with cancer receiving Paclitaxel- or Oxaliplatin-based chemotherapy — A pilot trial of cannabidiol. / Dominiak, Helena Sylow Heilmann; Hasselsteen, Simone Dyring; Nielsen, Sebastian Werngren; Andersen, Jens Rikardt; Herrstedt, Jørn.
In: Nutrients, Vol. 15, No. 13, 3014, 2023.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Prevention of taste alterations in patients with cancer receiving Paclitaxel- or Oxaliplatin-based chemotherapy — A pilot trial of cannabidiol
AU - Dominiak, Helena Sylow Heilmann
AU - Hasselsteen, Simone Dyring
AU - Nielsen, Sebastian Werngren
AU - Andersen, Jens Rikardt
AU - Herrstedt, Jørn
N1 - Publisher Copyright: © 2023 by the authors.
PY - 2023
Y1 - 2023
N2 - Introduction: Taste alteration is a common adverse effect of chemotherapy. This study aimed to investigate the effect of cannabidiol (CBD) on Lean Body Mass (LBM), and taste alterations during oxaliplatin- or paclitaxel-based chemotherapy. Methods: LBM was estimated by bioelectrical impedance analysis (BIA), and taste perception was evaluated by a randomized sensory test of six samples: sweet, salt, and umami, all in weak and strong concentrations. Taste perceptions were scored on visual analog scales. Patients in the intervention group received oral CBD 300 mg/day for 8 days; patients in the control group did not. Patients were followed for three cycles of chemotherapy. Results: Twenty-two/ten patients (intervention/control group) were eligible. No effects on LBM were demonstrated. At baseline, the control group was able to differentiate between weak and strong saltiness and weak and strong sweetness but lost this ability after three cycles of chemotherapy. At baseline, the intervention group was unable to differentiate between the concentrations but gained the ability to significantly differentiate between weak and strong sweetness (p = 0.03) and weak and strong saltiness (p = 0.04) after three cycles of chemotherapy and treatment with CBD. Conclusions: CBD may improve patients’ ability to differentiate taste strengths during chemotherapy.
AB - Introduction: Taste alteration is a common adverse effect of chemotherapy. This study aimed to investigate the effect of cannabidiol (CBD) on Lean Body Mass (LBM), and taste alterations during oxaliplatin- or paclitaxel-based chemotherapy. Methods: LBM was estimated by bioelectrical impedance analysis (BIA), and taste perception was evaluated by a randomized sensory test of six samples: sweet, salt, and umami, all in weak and strong concentrations. Taste perceptions were scored on visual analog scales. Patients in the intervention group received oral CBD 300 mg/day for 8 days; patients in the control group did not. Patients were followed for three cycles of chemotherapy. Results: Twenty-two/ten patients (intervention/control group) were eligible. No effects on LBM were demonstrated. At baseline, the control group was able to differentiate between weak and strong saltiness and weak and strong sweetness but lost this ability after three cycles of chemotherapy. At baseline, the intervention group was unable to differentiate between the concentrations but gained the ability to significantly differentiate between weak and strong sweetness (p = 0.03) and weak and strong saltiness (p = 0.04) after three cycles of chemotherapy and treatment with CBD. Conclusions: CBD may improve patients’ ability to differentiate taste strengths during chemotherapy.
KW - Cancer
KW - Cannabidiol
KW - Cannabis
KW - CBD
KW - Chemotherapy
KW - Chemotherapy-induced taste alterations
KW - Sensory test
KW - Taste
U2 - 10.3390/nu15133014
DO - 10.3390/nu15133014
M3 - Journal article
C2 - 37447339
AN - SCOPUS:85164670152
VL - 15
JO - Nutrients
JF - Nutrients
SN - 2072-6643
IS - 13
M1 - 3014
ER -
ID: 360812928